MA53655A - Traitement du cholangiocarcinome - Google Patents

Traitement du cholangiocarcinome

Info

Publication number
MA53655A
MA53655A MA053655A MA53655A MA53655A MA 53655 A MA53655 A MA 53655A MA 053655 A MA053655 A MA 053655A MA 53655 A MA53655 A MA 53655A MA 53655 A MA53655 A MA 53655A
Authority
MA
Morocco
Prior art keywords
cholangiocarcinoma
treatment
Prior art date
Application number
MA053655A
Other languages
English (en)
Inventor
Jacqueline Cirillo Bussolari
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MA53655A publication Critical patent/MA53655A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
MA053655A 2018-09-21 2019-09-19 Traitement du cholangiocarcinome MA53655A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862734501P 2018-09-21 2018-09-21

Publications (1)

Publication Number Publication Date
MA53655A true MA53655A (fr) 2021-12-29

Family

ID=68289904

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053655A MA53655A (fr) 2018-09-21 2019-09-19 Traitement du cholangiocarcinome

Country Status (16)

Country Link
US (1) US20220054483A1 (fr)
EP (1) EP3852756A1 (fr)
JP (1) JP2022501355A (fr)
KR (1) KR20210064274A (fr)
CN (1) CN112739347A (fr)
AU (1) AU2019342289A1 (fr)
BR (1) BR112021005271A2 (fr)
CA (1) CA3111866A1 (fr)
EA (1) EA202190826A1 (fr)
IL (1) IL281595A (fr)
JO (1) JOP20210052A1 (fr)
MA (1) MA53655A (fr)
MX (1) MX2021003320A (fr)
PH (1) PH12021550628A1 (fr)
SG (1) SG11202102546XA (fr)
WO (1) WO2020058432A1 (fr)

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
EP0951541B1 (fr) 1995-07-31 2005-11-30 Urocor, Inc. Biomarqueurs et cibles de diagnostic, de pronostic et de traitement du cancer de la prostate
US6218529B1 (en) 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
DE19802377A1 (de) * 1998-01-22 1999-08-19 Max Planck Gesellschaft Verwendung von Inhibitoren für die Behandlung von RTK-Überfunktions-bedingten Störungen, insbesondere von Krebs
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
SG154451A1 (en) 2005-05-23 2009-08-28 Novartis Ag Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1- yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactic acid salts
US8163923B2 (en) 2007-03-14 2012-04-24 Advenchen Laboratories, Llc Spiro substituted compounds as angiogenesis inhibitors
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
AR088941A1 (es) 2011-11-23 2014-07-16 Bayer Ip Gmbh Anticuerpos anti-fgfr2 y sus usos
HUE058219T2 (hu) * 2014-09-26 2022-07-28 Janssen Pharmaceutica Nv FGFR-mutánsgénpanel alkalmazása olyan rákbetegek azonosításában, akik FGFR-inhibitorral történõ kezelésre reszponzívak lesznek
SG11201706143SA (en) * 2015-03-25 2017-09-28 Nat Cancer Ct Therapeutic agent for bile duct cancer
AU2016341445B2 (en) * 2015-10-23 2020-08-27 Array Biopharma, Inc. 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2H)-one compounds as inhibitors of FGFR tyrosine kinases
WO2018141921A1 (fr) * 2017-02-06 2018-08-09 Janssen Pharmaceutica Nv Traitement du cancer
CA3100422A1 (fr) * 2018-05-16 2019-11-21 Debiopharm International, S.A. Schemas posologiques pour le traitement de tumeurs solides ayant une ou plusieurs alterations genetiques dans fgfr1, fgfr2 et/ou fgfr3

Also Published As

Publication number Publication date
JP2022501355A (ja) 2022-01-06
AU2019342289A1 (en) 2021-03-18
WO2020058432A1 (fr) 2020-03-26
SG11202102546XA (en) 2021-04-29
CN112739347A (zh) 2021-04-30
CA3111866A1 (fr) 2020-03-26
EA202190826A1 (ru) 2021-06-16
JOP20210052A1 (ar) 2021-03-18
PH12021550628A1 (en) 2022-02-14
BR112021005271A2 (pt) 2021-06-15
EP3852756A1 (fr) 2021-07-28
US20220054483A1 (en) 2022-02-24
IL281595A (en) 2021-05-31
MX2021003320A (es) 2021-05-14
KR20210064274A (ko) 2021-06-02

Similar Documents

Publication Publication Date Title
KR102680786B1 (ko) Cns 병태의 치료
MA46954A (fr) Méthodes de traitement d'états inflammatoires
MA46102A (fr) Composés de tétracycline et méthodes de traitement
MA49144A (fr) Polythérapies pour le traitement du cancer
MA47095A (fr) Traitement du palais mou
MA43135A (fr) Compositions et méthodes pour le du traitement du cancer
MA47501A (fr) Dérivé de di-nucléotides cycliques pour le traitement du cancer
MA56212A (fr) Compositions et méthodes de traitement du cancer
MA47719A (fr) Esketamine pour le traitement de la dépression
MA50264A (fr) Méthodes de traitement des infections de type hépatite b
MA48637A (fr) Polythérapies pour le traitement du cancer
MA47820A (fr) Traitement de la glycogénose de type iii
MA50409A (fr) Polythérapies pour le traitement du cancer
MA49248A (fr) Inhibiteurs de fgfr2 utilisés dans le traitement du cholangiocarcinome
MA45675A (fr) Méthodes et compositions permettant le traitement du cancer
MA47408A (fr) Traitement du cancer
MA49413A (fr) Traitement de gaz acide
MA46361A (fr) Traitement du cancer de la prostate
MA52627A (fr) Traitement du cancer
MA46061A (fr) Traitement ascaroside de maladies auto-immunes et inflammatoires
MA52216A (fr) Méthodes de traitement de la colite ulcéreuse
MA42999A (fr) Polythérapie pour le traitement de malignités
MA48730A (fr) Compositions et méthodes de traitement de synucléinopathies
MA42930A (fr) Traitement de maladies neurodégénératives
MA54860A (fr) Méthodes de traitement du myélome multiple